ARRY-380 To Advance Into Human PI Trial

Array BioPharma, Inc. (NASDAQ: ARRY) plans to initiate a Phase I trial this fall for ARRY-380, a selective, orally-active ErbB-2 inhibitor for metastatic breast cancer patients and perhaps those who are resistant to Genentech’s (NYSE: DNA) HER2 targeting blockbuster Herceptin.

The ARRY-380 candidate ErbB-2 inhibitor has shown efficacy and is well-tolerated in pre-clinical models of human cancer. ErbB-2 is a receptor kinase target that has been found to be over-expressed in breast and other cancers.